Werewolf Therapeutics Inc (HOWL)

Feb 07, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update - MarketBeat

Feb 07, 2025

Jan 28, 2025

Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World

Jan 28, 2025

Jan 24, 2025

Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 24, 2025

Jan 19, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat

Jan 19, 2025

Jan 17, 2025

Jane Street Group LLC Trims Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 17, 2025

Jan 14, 2025

Werewolf Therapeutics' SWOT analysis: stock faces challenges amid pipeline progress - Investing.com

Jan 14, 2025

Jan 14, 2025

Werewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP Securities - MarketBeat

Jan 14, 2025

Jan 14, 2025

JMP Securities Cuts Price Target for Werewolf Therapeutics (NASDAQ:HOWL) to $4.00/Share, Down from $12.00 - HPBL

Jan 14, 2025

Jan 14, 2025

Werewolf Therapeutics provides business update, highlights 2025 outlook - Yahoo Finance

Jan 14, 2025

Jan 13, 2025

Werewolf Therapeutics Provides Business Update - citybiz

Jan 13, 2025

Jan 13, 2025

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - GlobeNewswire

Jan 13, 2025

Jan 13, 2025

Werewolf Therapeutics Unveils Ambitious 2025 Pipeline Plans for Cancer Immunotherapy Programs - StockTitan

Jan 13, 2025

Jan 10, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Geode Capital Management LLC - Defense World

Jan 10, 2025

Jan 09, 2025

Barclays PLC Buys 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 09, 2025

Jan 03, 2025

State Street Corp Has $1.01 Million Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World

Jan 03, 2025

Dec 31, 2024

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 23.6% in December - MarketBeat

Dec 31, 2024

Dec 18, 2024

Werewolf Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com UK

Dec 18, 2024

Dec 18, 2024

Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 6.1% - Defense World

Dec 18, 2024

Dec 17, 2024

Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1% - MarketBeat

Dec 17, 2024

Dec 14, 2024

Werewolf Therapeutics' SWOT analysis: oncology stock's potential amid clinical trials - Investing.com Australia

Dec 14, 2024

Nov 23, 2024

HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World

Nov 23, 2024

Nov 20, 2024

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times

Nov 20, 2024

Nov 19, 2024

Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India

Nov 19, 2024

Nov 19, 2024

Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 19, 2024

Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 19, 2024

HC Wainwright Reaffirms "Buy" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat

Nov 19, 2024

Nov 15, 2024

PFM Health Sciences, LP Increases Stake in Werewolf Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 14, 2024

Nov 13, 2024

Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat

Nov 13, 2024

Nov 13, 2024

Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia

Nov 13, 2024

Nov 11, 2024

What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat

Nov 11, 2024

Nov 08, 2024

Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa

Nov 08, 2024

Nov 07, 2024

Werewolf Therapeutics Inc (HOWL) Quarterly 10-Q Report - Quartz

Nov 07, 2024

Nov 07, 2024

Werewolf Therapeutics reports promising trial data for cancer drug - Investing.com

Nov 07, 2024

Nov 07, 2024

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 07, 2024

Nov 07, 2024

Werewolf Therapeutics Presents Preclinical and Clinical - GlobeNewswire

Nov 07, 2024

Nov 07, 2024

Werewolf's WTX-330 Shows Promise in Phase 1 Trial: Melanoma Patient Responds to Novel IL-12 Therapy | HOWL Stock News - StockTitan

Nov 07, 2024

Nov 07, 2024

Werewolf Therapeutics Reports Breakthrough Cancer Trial Results Despite $16.7M Loss | HOWL Stock News - StockTitan

Nov 07, 2024

Nov 04, 2024

Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease - BioWorld Online

Nov 04, 2024

Oct 31, 2024

Werewolf Therapeutics expands pipeline with new IBD candidate By Investing.com - Investing.com South Africa

Oct 31, 2024

Oct 31, 2024

Werewolf Therapeutics expands pipeline with new IBD candidate - Investing.com

Oct 31, 2024

Oct 31, 2024

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - The Manila Times

Oct 31, 2024

Oct 31, 2024

Werewolf Therapeutics Announces Promising New Development - GlobeNewswire

Oct 31, 2024

Oct 26, 2024

WisdomTree Inc (NYSE: WT): Blank Check On Growth? - Stocks Register

Oct 26, 2024

Oct 23, 2024

Werewolf To Provide Clinical Update On WTX-330 - RTTNews

Oct 23, 2024